The Bio Genesis Priority

A disease does not need to kill at a historic rate to alter the course of a civilization. It can also act more slowly by leaving enough people unknowingly ill, or causing disease and morbidity to shift earlier in life, or reducing cognitive performance across a massive population. SARS-CoV-2 now presents that kind of risk.

The clearest recent warning comes from a 2026 JAMA Network Open study led by researchers at Massachusetts General Hospital. The study analyzed longitudinal electronic health records from 457,950 adults with documented COVID-19 across 58 hospitals and affiliated clinics in four United States regions. A validated computational phenotyping system identified postacute sequelae of SARS-CoV-2 infection, commonly called Long COVID, in 16.28% of patients. That is approximately one in six people in the study and more than twice the share detected through conventional diagnostic code based surveillance (Tian et al., 2026). Millions of patients may be receiving fragmented care for dysautonomia, metabolic disease, respiratory problems, fatigue, or cognitive symptoms without ever receiving the diagnostic label that would connect those conditions to a prior Covid19 infection (Tian et al., 2026).

Three findings make the study especially important. First, the 16.28% estimate shows that the burden may be substantially higher than diagnostic coding suggests. Second, cumulative Long COVID prevalence increased across all four regions through mid-2024. Statistically significant quarterly increases were observed in three regions, while the smaller Southeast Texas cohort showed a similar but nonsignificant trend. This pattern reflects the continuing addition of new cases well after the severe opening waves of the pandemic. Third, 89.31% of the patients identified with Long COVID developed at least one chronic condition requiring ongoing clinical management. That group represented 14.54% of the cohort (Tian et al., 2026).

New evidence from the United Kingdom gives this prevalence problem an institutional dimension. The REACH-OUT programme found that 23% of infected UK healthcare workers surveyed from December 2020 through March 2021 reported symptoms lasting at least five weeks. In a later survey conducted from October 2021 through October 2022, 27% reported symptoms lasting at least 12 weeks. Its global systematic review found that 26.5% of healthcare workers followed for a full year remained symptomatic. These cohorts used different definitions and reflect an early-pandemic workforce with unusually high exposure, so the figures should be understood as a sector-specific warning. When Long COVID concentrates among the people responsible for delivering care, it creates a feedback loop: demand on the health system rises as the capacity of that same system is reduced (Al-Oraibi et al., 2025a, 2025b).

The civilizational burden can therefore be evaluated along three connected dimensions.

1. Mapping Long COVID Prevalence

Prevalence is the visible base of the problem: how many people develop postacute disease, how many remain ill, how many recover, and how many relapse or acquire additional burden after reinfection. Current active prevalence and cumulative prevalence must be measured separately. The first estimates how many people are ill now (difficult to know). The second records how many people have ever crossed into Long COVID. Tian and colleagues measured the cumulative share and explicitly cautioned that their data could not reliably determine when every condition resolved (Tian et al., 2026).

That distinction does not weaken the warning. Cumulative prevalence shows how widely the disease has penetrated the population and how many people may carry residual vulnerability, recurrent symptoms, or chronic diagnoses following an initial infection. Active prevalence shows the immediate demand on health care, disability systems, families, and employers. Both belong in any serious assessment of national capacity, as both are being impacted without a clear line of sight.

The global literature remains heterogeneous because studies use different definitions, populations, follow-up periods, and methods. This makes a single universal percentage premature. It does not make the burden small. A 2025 economic review summarized estimates reaching roughly 400 million cumulative cases worldwide and a possible annual economic impact approaching $1 trillion, while also emphasizing the uncertainty behind global extrapolation (Bansal, 2025). The correct response to uncertainty at this scale is stronger investigation and applied AI solutions.

2. Measuring Acceleration of Morbidity

Morbidity means illness, disability, and loss of healthy function. Morbidity acceleration is the possibility that chronic conditions appear earlier, accumulate faster, or persist longer after SARS-CoV-2 infection than they would have in an otherwise comparable population. This is a hypothesis that must be tested longitudinally. It is already a legitimate risk.

HIV research provides a useful precedent for how to recognize it. In a landmark 2011 study, treated adults with HIV between ages 41 and 50 had a prevalence of multiple age-associated conditions comparable to uninfected adults between ages 51 and 60. The conditions included cardiovascular disease, hypertension, diabetes, bone fractures, and renal failure. The study helped shift attention from survival alone toward accumulation of chronic disease (Guaraldi et al., 2011).

The comparison is methodological. Long COVID and HIV are distinct diseases with different biology, transmission, treatment, and prognosis. The lesson is that population health can deteriorate through a shift in the timing of morbidity even when immediate mortality improves. A society becomes older in functional terms when large numbers of people begin carrying the health burdens of later life years earlier than expected; often noticed in retrospect within retirement-age cohorts.

COVID-19 has already produced the signal that warrants this measurement. In a three-year cohort of 135,161 people with SARS-CoV-2 infection and more than 5.2 million controls, postacute risks generally declined over time but did not disappear. Among people whose acute infections did not require hospitalization, excess neurologic, pulmonary, and gastrointestinal burden remained detectable in the third year. Among those hospitalized, mortality risk and multisystem health loss remained elevated through year three (Cai et al., 2024). The 2026 hospital network study adds another warning: nearly nine in ten identified Long COVID patients developed a chronic condition requiring continued management (Tian et al., 2026).

The average age of cardiovascular, metabolic, neurologic, renal, or immune disease is moving downward; the pandemic has likely changed the morbidity curve of the global, human, population.

3. Reducing Global Cognitive Decline

The neurological burden is wider than the population carrying a Long COVID code. Cognitive Long COVID can include impaired memory, attention, processing speed, executive function, planning, and reasoning. These functions determine whether people can learn, work, make decisions, regulate complex systems, and detect errors. A small loss at the individual level can become consequential when distributed across millions of people and repeated across institutions.

The strongest population evidence comes from a 2024 New England Journal of Medicine study of 112,964 adults who completed an eight-task cognitive assessment. Participants with unresolved symptoms lasting at least 12 weeks had a global cognitive score 0.42 standard deviations below the no-COVID comparison group. The more consequential population finding was that participants who had recovered from shorter illness and those whose prolonged symptoms had resolved still showed average deficits of 0.23 and 0.24 standard deviations, respectively. Memory, reasoning, and executive function were among the domains examined (Hampshire et al., 2024).

A 2025 prospective community cohort found faster cognitive decline in older adults who had been hospitalized with COVID-19, particularly in memory and executive function, while nonhospitalized infection was not associated with faster decline in that cohort (Demmer et al., 2025). Earlier longitudinal imaging from the UK Biobank also found structural brain changes and greater cognitive decline after infection, including among many people who had not been hospitalized, although the clinical meaning and long-term course of those changes remain uncertain (Douaud et al., 2022).

Taken together, the evidence supports a disciplined conclusion: measurable effects extend into non-severe cases, or people who recovered and were never diagnosed with Long COVID. Research has not yet established the permanence, universality, or future population distribution of those effects. That uncertainty defines the scale of the unanswered problem.

A three-factor gradient of civilizational risk

The civilizational risk of Long COVID should be tracked as a gradient produced by three interacting factors:

1. Long COVID prevalence: the proportion of infected people who develop postacute disease, the proportion currently ill, the duration of illness, recovery rates, relapse, and, most importantly, the added effect of reinfection.

2. Increased morbidity: the excess incidence of chronic disease, the age at which it appears, the speed at which multiple conditions accumulate, and the healthy years of life lost.

3. Cognitive decline: objective changes in memory, attention, processing speed, executive function, and reasoning among people diagnosed with or without Long COVID.

Any one of these factors creates pressure. High prevalence strains health systems and labor markets. Earlier morbidity increases years lived with disability and brings future medical demand into the present. Cognitive decline reduces the quality of decisions made throughout families, schools, firms, governments, and safety-critical institutions; and each of these has immense compounding negative effects. When all three rise together, the risk becomes structural.

That is the claim civilization must now take seriously. Long COVID is an accumulating systems problem whose burden is being divided across diagnostic silos and therefore understated. The immediate task is to build testing capable of seeing it: consistent case definitions, linkage across specialties, current and cumulative prevalence estimates, long-term matched cohorts, preinfection cognitive baselines where available, and direct measurement of morbidity acceleration at onset.

The decisive question is no longer whether Long COVID exists or whether it can be disabling. The question is whether repeated SARS-CoV-2 exposure is gradually changing the health span, life span, and cognitive capacity of the population. The evidence is sufficient to make that a central public health quest. The federal Bio Genesis Mission provides a national structure for precisely this kind of work. Led by the National Institutes of Health as the biomedical component of the broader Genesis Mission, it is designed to apply AI, advanced computing, clinical infrastructure, and federal data resources to predict complex living systems, accelerate drug discovery, and investigate the root causes of chronic disease (National Institutes of Health, 2026; White House, 2026). Long COVID should become an explicit Bio Genesis challenge.

References

National Institutes of Health. (2026, August 11). Bio Genesis Mission. https://www.nih.gov/bio-genesismission

White House. (2026, July 22). Trump Administration announces more than $5 billion for the Genesis Mission, a national mission on AI for science. https://www.whitehouse.gov/releases/2026/07/45502/

Cai, M., Xie, Y., Topol, E. J., & Al-Aly, Z. (2024). Three-year outcomes of post-acute sequelae of COVID-19. Nature Medicine, 30, 1564–1573. https://doi.org/10.1038/s41591-024-02987-8

Al-Oraibi, A., Woolf, K., Naidu, J., et al. (2025a). Global prevalence of long COVID and its most common symptoms among healthcare workers: A systematic review and meta-analysis. BMJ Public Health, 3(1), e000269. https://doi.org/10.1136/bmjph-2023-000269

Al-Oraibi, A., Martin, C. A., Woolf, K., Bryant, L., Nellums, L. B., Tarrant, C., Khunti, K., & Pareek, M. (2025b). Prevalence of and factors associated with long COVID among diverse healthcare workers in the UK: A cross-sectional analysis of a nationwide study (UK-REACH). BMJ Open, 15(1), e086578. https://doi.org/10.1136/bmjopen-2024-086578

Bergeson, L. (2026, August 27). 1 in 4 infected UK healthcare workers developed long COVID, report shows. CIDRAP. https://www.cidrap.umn.edu/covid-19/1-4-infected-uk-healthcare-workers-developed-long-covid-report-shows

Demmer, R. T., Cornelius, T., Kraal, Z., et al. (2025). COVID-19 and cognitive change in a community-based cohort. JAMA Network Open, 8(6), e2518648. https://doi.org/10.1001/jamanetworkopen.2025.18648

Douaud, G., Lee, S., Alfaro-Almagro, F., et al. (2022). SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature, 604(7907), 697–707. https://doi.org/10.1038/s41586-022-04569-5

Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011). Premature age-related comorbidities among HIV-infected persons compared with the general population. Clinical Infectious Diseases, 53(11), 1120–1126. https://doi.org/10.1093/cid/cir627

Hampshire, A., Azor, A., Atchison, C., Trender, W., Hellyer, P. J., Giunchiglia, V., Husain, M., Cooke, G. S., Cooper, E., Lound, A., Donnelly, C. A., Chadeau-Hyam, M., Ward, H., & Elliott, P. (2024). Cognition and memory after COVID-19 in a large community sample. The New England Journal of Medicine, 390(9), 806–818. https://doi.org/10.1056/NEJMoa2311330

Bansal, A. (2025). Economic burden of long COVID: Macroeconomic, cost-of-illness and microeconomic impacts. npj Primary Care Respiratory Medicine, 35, Article 53. https://doi.org/10.1038/s41533-025-00460-8

Tian, J., Azhir, A., Decaro, M., Chau, N., Hügel, J., Morris, M., Cheng, J., Fard, P., Bassett, I. V., Bell, D. S., Bernstam, E. V., Visweswaran, S., Klann, J. G., Murphy, S. N., & Estiri, H. (2026). Long COVID persistence and surveillance gaps across 58 US hospitals. JAMA Network Open, 9(5), e2614909. https://doi.org/10.1001/jamanetworkopen.2026.14909